**Name of journal: World Journal of Cardiology**

**ESPS Manuscript NO: 7861**

**Columns: Review**

**Is reversal of endothelial dysfunction still an attractive target in modern cardiology?**

Mordi I *et al*. Endothelial dysfunction in modern cardiology

Ify Mordi, Nikolaos Tzemos

**Ify Mordi, Nikolaos Tzemos,** Institute of Cardiovascular and Medical Sciences, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow G12 8TA, United Kingdom

**Author contributions:** Mordi I and Tzemos N were sole contributors to this paper.

**Correspondence to: Dr. Nikolaos Tzemos,** Institute of Cardiovascular and Medical Sciences, University of Glasgow, British Heart Foundation Glasgow Cardiovascular Research Centre, 126 University Place, Glasgow G12 8TA, United Kingdom. niko.tzemos@glasgow.ac.uk

**Telephone:** +44-141-3302079 **Fax:** +44-141-3306697

**Received:** December 3, 2013 **Revised:** April 17, 2014

**Accepted:** May 28, 2014

**Published online:**

**Abstract**

Although the endothelium has a number of important functions, the term endothelial dysfunction is commonly used to describe impairment in its vasodilatory capacity. There have been numerous studies evaluating the relationship between endothelial dysfunction and cardiovascular disease, however assessment of endothelial function is perhaps still primarily thought of as a research tool and has not reached widespread clinical acceptance. In this review we explore the relationship between endothelial dysfunction and cardiovascular disease, its prognostic significance, methods of pharmacological reversal of endothelial dysfunction, and ask the question, is reversal of endothelial dysfunction still an attractive target in modern cardiology?

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Endothelium; Vascular; Nitric oxide; Atherosclerosis; Risk factors; Flow-mediated dilatation

**Core tip:** There is an abundance of evidence suggesting that endothelial dysfunction is present throughout a wide spectrum of cardiovascular disease and is an independent indicator of adverse prognosis. Despite this, perhaps due to lack of standardisation of investigative techniques, endothelial function assessment is not yet routinely undertaken, despite a number of therapies which have been shown to have beneficial effects on the endothelium. More studies are required to judge whether assessment of endothelial function can impact on clinical management and prognosis.

Mordi I, Tzemos N. Is reversal of endothelial dysfunction still an attractive target in modern cardiology? *World J Cardiol* 2014; In press

**Available from:**

**DOI:**

**INTRODUCTION**

For many years the vascular endothelium was thought of as simply a selectively permeable barrier between the intra- and extravascular compartments. However, discovery by Furchgott and Zadawski[[1](#_ENREF_1)] that the large blood vessels of mammals only dilate if the endothelium is intact due to its response to nitric oxide (NO) was the first step in our understanding that the endothelium is a key modulator of cardiovascular health. Indeed, the integrity of the vascular endothelium is essential for providing adequate blood flow and antithrombotic activity. While these are key functions of the endothelium, in the context of cardiovascular health, the key function of the endothelium is maintenance of vasodilatation in response to NO. The healthy human endothelium maintains a vasodilated state as a baseline, in part due to NO production from L-arginine by nitric oxide synthase. NO then diffuses into the endothelium, leading to increased cyclic GMP production and vasodilatation[[2](#_ENREF_2)]. Damage to the endothelium, whether anatomical or functional can cause a disturbance of this pathway leading to endothelial dysfunction. There are three potential mechanisms that can lead to endothelial dysfunction (either in isolation or combination): reduced production of NO[[3](#_ENREF_3)]; reduced availability of NO[[4](#_ENREF_4)] or antagonism of NO by endothelium derived contracting factors[[5](#_ENREF_5)]. Indeed, although NO is the main endothelium-derived relaxing factor there are other factors active on the endothelium, all of which play a key role in its health. Other endothelium-derived relaxing factors include prostacyclin and endothelium-derived hyperpolarizing factor, both of which can show increased activity in response to a decrease in NO. Meanwhile, there are several endothelium-derived contracting factors causing vasoconstriction such as endothelin-1, thromboxane A2 and prostaglandin H2. Nevertheless, the majority of clinical studies have concentrated on NO, and this will be the focus of our review.

NO has a number of vascular protective roles including inhibition of platelet aggregation and leucocyte adhesion, however endothelial dysfunction can be simply described as the imbalance of vasodilatation and vasoconstriction caused by vasoactive substances acting on the endothelial cells[[6](#_ENREF_6)]. Endothelial dysfunction is present in a number of cardiovascular conditions such as diabetes, hypercholesterolemia and hypertension and seems to be an important feature in the pathogenesis of the atherosclerotic disease process.

In this review, we will discuss the association of endothelial dysfunction with the cardiovascular disease, its prognostic relevance, methods for reversing endothelial dysfunction and their impact on outcome.

**HOW DO WE QUANTIFY ENDOTHELIAL FUNCTION CLINICALLY?**

Theoretically endothelial function can be measured in any artery. In most methods the endogenous NO-dependent vasodilation is measured using a pharmacological agonist such as acetylcholine (Ach) or other substances which stimulate endogenous NO production. Comparison is then made with NO-independent vasodilatation using substances such as glyceryl trinitrate (GTN). Invasive measurement of the coronary artery response to acetylcholine is a validated measurement of coronary artery endothelial function and was the first method used to demonstrate endothelial function[[7](#_ENREF_7), [8](#_ENREF_8)]. Using quantitative coronary angiography the change in diameter of the artery can be measured in response to Ach. In dysfunctional coronary arteries Ach causes reduced vasodilatation or apparently paradoxical vasoconstriction due to the unopposed direct smooth muscle muscarinic action of Ach at apparently high concentrations[[9](#_ENREF_9)].

Non-invasive measures include what is considered by many as gold standard, venous occlusion plethysmography. This technique is used to assess forearm blood flow (in the brachial artery) in response to an inflated blood pressure cuff. The inflation of the cuff occludes venous return (but not arterial inflow) thus creating a “reservoir” of blood within the anatomically isolated limb region (forearm). The rate of vessel swelling can be measured as a surrogate for vascular resistance while the volume increases in proportionally in relation to the forearm blood flow[[10](#_ENREF_10)]. Endothelial function, which is closely related to NO biocactivity, can be measured by constructing dose-response curves to escalating doses of Ach and measuring the rate of change in arm swelling by strain gauge. One advantage of this technique is that measurement of forearm blood flow (FBF) in the contralateral arm can be used as a further within patient control, allowing optimal reproducibility[[11](#_ENREF_11)]. Nevertheless, the requirement for arterial cannulation may limit patient tolerability and repeatability.

Flow-mediated dilation (FMD) is probably the most common method of endothelial function assessment. This technique involves using ultrasound to measure the peripheral arterial response (again, usually the brachial artery) to temporary ischemia caused by inflation and release of a cuff. Release of the cuff causes an increase in blood flow and therefore shear stress which stimulates NO release and leads to vasodilatation. The increase in diameter of the blood vessel from baseline can be measured by two dimensional ultrasound and is related (but not exclusive) to NO bioavailability, giving an excellent measure of endothelial function which can again be compared to dilatation using endothelium-independent vasoactive substances[[12](#_ENREF_12)]. Of note, FMD has been shown to have excellent correlation with coronary endothelial function[[13](#_ENREF_13)].

A more recently developed method of assessment is peripheral arterial tonometry (PAT). This technique allows non-invasive measurement of vasomotor function by measuring plethysmographic changes in the fingertip pulse. Again, the endothelium-dependent response can be ascertained by arterial cuff occlusion[[14](#_ENREF_14)]. PAT has also been shown to correlate well with both coronary endothelial function and FMD[[15](#_ENREF_15), [16](#_ENREF_16)].

**WHAT IS THE CLINICAL RELEVANCE OF ENDOTHELIAL DYSFUNCTION?**

While several methods have been developed to assess endothelial function in different arterial beds, there can only be any benefit to quantification of endothelial dysfunction if there is evidence that it can be used to identify groups with an adverse prognosis.

Several studies have shown a relationship between endothelial dysfunction, coronary disease risk factors and atherosclerosis. One of the earliest studies revealing this relationship was carried out by Ludmer *et al*[[8](#_ENREF_8)] who discovered that in patients with both mild and advanced coronary artery disease (CAD) there was paradoxical vasoconstriction induced by acetylcholine. Evidence of endothelial dysfunction has also been noted in patients with risk factors for CAD but without angiographically significant CAD, suggesting that endothelial dysfunction may indeed predate the development of clinically significant atherosclerosis[[17](#_ENREF_17), [18](#_ENREF_18)]. Age[[19](#_ENREF_19)], diabetes mellitus[[20-22](#_ENREF_20)], smoking (both active and passive)[[23-25](#_ENREF_23)], hypertension[[26](#_ENREF_26)] and hyperlipidemia[[27](#_ENREF_27), [28](#_ENREF_28)] have all been associated with endothelial dysfunction prior to the development of clinically significant CAD. Furthermore, patients with a combination of risk factors (such as smoking and hypercholesterolemia) have been shown to have worse endothelial function than those with a single risk factor[[29](#_ENREF_29)].

The presence of endothelial dysfunction has been shown to be a predictor of cardiovascular events independent of the arterial bed studied or method of assessment[[30](#_ENREF_30),[31](#_ENREF_31)]. Much of this effect is due to the fact that endothelial dysfunction is invariably present whenever there is end-organ damage. This is clinically manifested as atherosclerosis, left ventricular hypertrophy, small vessel brain ischemia and renal impairment, leading to significant morbidity and mortality[[32-34](#_ENREF_32)]. Not unreasonably, endothelial function assessment could be considered as the barometer of vascular health[[35](#_ENREF_35)]. Large studies investigating the prognostic value of endothelial function assessment using FMD are summarized in Table 1.

So why has endothelial dysfunction assessment not been adopted more widely clinically? As we have discussed, FMD appears to be the most robust and widely used technique, yet it very rarely appears in any clinical guidelines. One reason may be that although FMD does have predictive value, there are of course several other risk factors that may be easier to assess which are also predictors of adverse cardiac outcome[[31](#_ENREF_31)]. Secondly, although many studies have reported the excellent reproducibility and variability of FMD measurement in multiple institutions[[36-39](#_ENREF_36)], these studies all rely on following an “ideal” protocol for obtaining FMD measurements. According to a recent paper published by the European Society of Cardiology, this includes 10 min rest for the patient prior to measurement, correct cuff placement, an occlusion time of 5 min and measurement 45-60 s after cuff release[[40](#_ENREF_40)]. Clearly, following this prescribed methodology takes some time and is prohibitive to its use within the clinical setting, however, not using these techniques can lead to inaccurate measurements, thus diluting the utility of FMD measurements. Automated analysis software may well overcome some of the difficulties regarding standardization of results[[37](#_ENREF_37)], however, when it is much simpler to check a cholesterol level or measure a blood pressure, it is easy to see why FMD has perhaps not yet penetrated the clinical realm. Also, FMD is strongly influenced by baseline brachial artery diameter, and changes in FMD tend to vary based on this[[41](#_ENREF_41)]. Finally, the absence of normal values makes it difficult to provide any clinically relevant recommendations to non-experts in the field of endothelial function assessment.

**ENDOTHELIAL DYSFUNCTION IN ASYMPTOMATIC PATIENTS**

In asymptomatic patients, most clinicians use the assessment of risk factors, such as the Framingham Risk score, to assess cardiovascular risk[[42](#_ENREF_42)]. Studies looking at the independent prognostic value of FMD in prediction of adverse events in asymptomatic patients have shown mixed results. Suzuki *et al*[[43](#_ENREF_43)], in the Northern Manhattan Study, evaluated 819 patients with cardiovascular risk factors and showed that patients with metabolic syndrome and endothelial dysfunction (measured by FMD) were at a higher risk for stroke, MI or cardiovascular death than those without endothelial dysfunction. In one of the largest studies to date, Yeboah *et al*[[44](#_ENREF_44)] reported that in 2792 patients with 5 years of follow up, FMD was an independent predictor of a poor outcome, however it did not appear to add much to the overall predictive model. Further large cohort studies have also shown that FMD is an independent predictor of adverse events, although there is some question as to whether the small incremental increase in prediction provided by the assessment of endothelial function mandates the routine clinical use of FMD[[31](#_ENREF_31),[44-46](#_ENREF_44)]. Indeed, other large studies have not found incremental predictive value with use of FMD. A large study of 842 asymptomatic patients in the Northern Manhattan Study found that although FMD did predict adverse outcomes it was not an independent predictor when included in a multivariable analysis including traditional cardiac risk factors[[47](#_ENREF_47)]. Two further studies found that while FMD was not an independent predictor of adverse events, several components of endothelial function measurement, such as hyperemic velocity and assessment of resistance artery endothelial function, were[[48](#_ENREF_48),[49](#_ENREF_49)]. In general, there is still doubt that endothelial dysfunction is a predictor of adverse cardiovascular events in asymptomatic patients.

**ENDOTHELIAL DYSFUNCTION IN ESTABLISHED CAD (CHRONIC STABLE CAD)**

Endothelial dysfunction in the coronary arteries is closely related to systemic endothelial dysfunction[[13](#_ENREF_13)]. In patients with CAD the presence of severe endothelial dysfunction has been shown to be a predictor of cardiac death, myocardial infarction or revascularization[[50](#_ENREF_50)]. These results have been replicated in other large studies[[51-53](#_ENREF_51)]. Endothelial dysfunction has also been related to adverse plaque characteristics (such as lipid-rich necrotic cores) in this group of patients[[54](#_ENREF_54),[55](#_ENREF_55)]. FMD has also been shown to be an independent predictor of in-stent restenosis in patients with single vessel coronary artery disease undergoing percutaneous coronary intervention[[56](#_ENREF_56)]. Elsewhere in the vascular tree, FMD has also been shown to be a predictor of post-operative MACE in patients with hypertension[[57](#_ENREF_57)], early peripheral arterial disease[[58](#_ENREF_58)] and those undergoing vascular surgery[[59](#_ENREF_59)].

**ENDOTHELIAL DYSFUNCTION IN ACUTE CORONARY SYNDROMES**

Over the past decade there has been an increasing realization that acute coronary syndromes (ACS) cannot be predicted simply by risk factors or even the presence of obstructive CAD[[60](#_ENREF_60),[61](#_ENREF_61)]. The development of the “vulnerable plaque” concept that leads to ACS (and sudden cardiac death) is influenced by omnipresent endothelial dysfunction *via* several methods. Endothelial dysfunction leads to reduced expression of anti-inflammatory mediators, leading to plaque destabilization[[62](#_ENREF_62)]. In particular, Endothelin-1, a potent vasoconstrictor, is released significantly more by the dysfunctional endothelium as well as directly at the site of unstable coronary plaque lesions[[63](#_ENREF_63)]. The predominant vasoconstriction of the dysfunction coronary artery may cause plaque rupture directly[[64](#_ENREF_64)]. Finally, the dysfunctional endothelium also has reduced anti-thrombotic tendency allowing thrombus formation[[65](#_ENREF_65)].

Endothelial dysfunction is also a predictor of adverse outcome in patients after ACS. Improvement of endothelial function post-ACS is associated with improved prognosis[[66](#_ENREF_66),[67](#_ENREF_67)]. Endothelial dysfunction has also been shown to lead to adverse remodeling post-ACS[[68](#_ENREF_68)].

**ENDOTHELIAL DYSFUNCTION IN HEART FAILURE**

There is ample evidence to suggest that endothelial function is impaired in patients with both acute and chronic heart failure[[69](#_ENREF_69)]. NO has been shown to be involved in myocardial relaxation[[70](#_ENREF_70)], and reduction in NO availability (for the same reasons as seen in the vasculature) can impair left ventricular relaxation, causing diastolic dysfunction. The presence of diastolic dysfunction is associated with impaired FMD in patients with established CAD[[71](#_ENREF_71)]. The presence of endothelial dysfunction has also been associated with perfusion defects and reduced coronary flow in patients with suspected coronary artery disease thus potentially leading to impaired ventricular function[[72](#_ENREF_72),[73](#_ENREF_73)]. In chronic heart failure there may be a vicious circle effect, by which the reduction of cardiac output leads to a decrease in vascular shear stress and NO production, therefore causing further worsening of endothelial function[[74](#_ENREF_74)]. FMD has also been shown to be a predictor of adverse outcome in heart failure patients[[75-78](#_ENREF_75)].

In acute heart failure, there is also a reduction in NO availability leading to vasoconstriction and increased vascular stiffness, increasing afterload. There is also increased endothelin-1 production and oxidative stress, again placing further strain on the heart and vasculature[[79](#_ENREF_79),[80](#_ENREF_80)]. Coronary artery endothelial dysfunction has been shown to predict progression of allograft vasculopathy and mortality in patients with orthoptic heart transplantation[[81](#_ENREF_81),[82](#_ENREF_82)].

Endothelial dysfunction is associated with adverse outcome in patients with LV dysfunction[[83-85](#_ENREF_83)]. It has also been shown to be a good predictor of response to cardiac resynchronization therapy (CRT) [[86](#_ENREF_86)].

**CAN ENDOTHELIAL DYSFUNCTION BE REVERSED?**

We have shown that there is substantial evidence to support the role of endothelial dysfunction in the development and progression of cardiovascular disease and its prognostic role. Because of this there has been a significant interest in finding methods to ameliorate endothelial dysfunction. Despite many drug classes being evaluated, only a few have shown concrete benefits on the endothelium. Large clinical studies evaluating pharmacological endothelial dysfunction reversal are summarized in Table 2.

Some of the most studied drug classes are those that act on the renin-angiotensin system, namely angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor antagonists (ARBs). These drugs have several anti-oxidant and anti-inflammatory effects, reducing superoxide (thus reducing oxidative stress) and endothelin-1 activity[[87](#_ENREF_87)]. Angiotensin II stimulates angiotensin type 1 receptors (AT1) to mediate arteriolar vasoconstriction and remodelling, superoxide anion production, renal sodium reabsorption, aldosterone secretion and endothelin-1 release[[88](#_ENREF_88)]. Many of these actions affect the vascular endothelium adversely. On the other hand stimulation of the angiotensin type 2 (AT2) receptor by angiotensin has mainly opposing actions to those of AT1 stimulation and recently has been shown to contribute to endothelial NO release[[89](#_ENREF_89)]. AT2 production can be reduced by angiotensin converting enzyme inhibitors which also increase both tissue and plasma bradykinin by inhibiting kininase II[[90](#_ENREF_90)]. By stimulating the B2 receptors, bradykinin mediates the release of NO, prostacyclin and the endothelial hyperpolarizing factor (EDHF); agents that produce vasodilation[[91-93](#_ENREF_91)]. The large TREND study provided evidence that quinapril was able to reverse endothelial dysfunction[[94](#_ENREF_94)]. The beneficial effects of ACEIs have been replicated by several other studies[[95-98](#_ENREF_95)]. Angiotensin-II receptor antagonists have also shown similar results[[99](#_ENREF_99), [100](#_ENREF_100)].

Spironolactone and eplerenone, which have mineralocorticoid receptor antagonist activity have received much attention recently. They have been reported to improve NO bioactivity in patients with heart failure[[101](#_ENREF_101)]. The mechanism(s) by which aldosterone impairs endothelial function is unclear. Aldosterone enhances vascular responsiveness to pressor agents such as norepinephrine and angiotensin II[[102](#_ENREF_102)]. Also, aldosterone can cause direct vascular smooth muscle contraction *via* a non-genomic pathway that has not yet been characterised. Both drugs have however been shown to improve endothelial function in patients with heart failure and hypertension[[103-106](#_ENREF_103)].

Beta-blockers and diuretics have generally been shown to have no effect on endothelial function however, newer beta-blockers such as nebivolol and carvedilol have shown some beneficial effects on reversal of endothelial dysfunction[[107-109](#_ENREF_107)]. Nebivolol has a direct effect on NO synthase while carvedilol has some antioxidant properties. Calcium channel antagonists also improve endothelial dysfunction by several pathways, particularly in the coronary microvasculature by indirectly increasing in intracellular smooth muscle cell cGMP, which is the second messenger of NO and mediates vasodilation[[110](#_ENREF_110),[111](#_ENREF_111)]. Two additional mechanisms have been described to explain the effects of calcium channel blocker in the forearm circulation. The first explanation is that most calcium channel blockers have antioxidant activities, reducing production of superoxide anions[[88](#_ENREF_88),[89](#_ENREF_89)]. The second explanation involves a reduction in endothelin-1 release by calcium channel blockers. Endothelin-1 is a potent vasoconstrictor and it is released from the endothelium[[112](#_ENREF_112)]. Normally, there is a balance between vasoconstrictive and vasodilating substances in the vasculature but in hypertension, the bioavailability of endothelin might be increased in parallel with a reduction in NO bioactivity. It has shown that calcium channel blockers improved NO bioactivity by reducing endothelin release[[100](#_ENREF_100),[101](#_ENREF_101)]. In addition, Cardillo *et al*[[113](#_ENREF_113)] have recently shown that in patients with essential hypertension, the increased endothelin activity is partly responsible for the increased vascular tone. Hence, in a model where vasoconstrictive activity is increased, such as hypertension, a reduction of endothelin release would improve NO bioactivity. CCBs may also improve other aspects of endothelial dysfunction, reducing tissue plasminogen activator activity, thus reducing thrombogenic risk by decreasing platelet activation[[114](#_ENREF_114)].

Statins also have proven beneficial effects on endothelial dysfunction in addition to their effects on lipids[[115-118](#_ENREF_115)]. Reduction in LDL-cholesterol is thought to be the main method by which statins improve endothelial function, however, they also enhance expression and activity of NO synthase and reduce C-reactive protein (which has deleterious effects on the endothelium) [[119](#_ENREF_119),[120](#_ENREF_120)]. On a similar, intriguing, theme of non-antihypertensive therapies improving endothelial function, recent studies have also suggested that drugs such as metformin[[121](#_ENREF_121)], ranolazine[[122](#_ENREF_122)] and allopurinol[[123](#_ENREF_123)] may also improve endothelial function.

**DOES REVERSAL OF ENDOTHELIAL DYSFUNCTION HAVE ANY PROGNOSTIC IMPACT?**

Given that several classes of drugs do seem to lead to an improvement in endothelial function, the next step is to consider whether these effects are translated into a prognostic benefit. There are however only a few studies which address this issue. Modena *et al*[[124](#_ENREF_124)] evaluated 400 post-menopausal women with hypertension and endothelial dysfunction in an attempt to assess whether an improvement in FMD using antihypertensive drugs would predict a better prognosis. The authors found that improvement in endothelial function after 6 mo of therapy was associated with a much reduced event rate (6% *vs* 21.3% in those patients with persistently impaired endothelial dysfunction). One problem might perhaps be the fact that therapeutic options which improve endothelial function also have other beneficial effects on the cardiovascular system independent of their vasodilatory contribution. A recent study in patients with heart failure showed that patients in whom endothelial function improved following institution of optimal medical therapy had a much better prognosis than those in whom there was no improvement (hazard ratio 3.0 for those with persistently impaired endothelial function) [[78](#_ENREF_78)].

Furthermore, confounding effects of medications also need to be considered–for example, hormone replacement therapy with estrogens in post-menopausal women does cause vasodilatation, however this beneficial effect is negated by their pro-thrombotic tendency. Another potential role for identification of endothelial dysfunction is that of screening. Given that there is abundant evidence to suggest that endothelial dysfunction is present before the development of clinically significant cardiovascular disease it might be beneficial to identify patients at potential risk of future events and offer disease modifying therapy. Again however this question has not yet been answered.

While numerous drugs that improve endothelial dysfunction have been shown to improve mortality, very few studies have specifically looked at the beneficial prognostic effects of endothelial dysfunction. This is presumably because when designing studies investigating these drugs it is very difficult to isolate the effect of endothelial dysfunction reversal given the multi-site action of drugs such as ACE inhibitors and statins. Of course, as the beneficial effects of these drugs are now well established, trials specifically looking at the prognostic benefit of endothelial dysfunction are perhaps less of a priority.

**CONCLUSION**

In this review we have demonstrated the methods of endothelial function assessment, the significance of endothelial dysfunction (particularly as a precursor) to cardiovascular disease and its prognostic significance. Several aspects need further exploration. First, despite the widespread use of FMD in clinical trials, is it the best way of assessing endothelial dysfunction? Certainly, the failure of the technique to obtain widespread use in a clinical setting despite many years of use in clinical trials and a reasonable amount of prognostic evidence behind it would suggest that it may never be adopted in the cardiology community. However, the failing of FMD seems to be more due to technical issues (such as the time taken to measure it and operator variability) rather than a disbelief in its results or the importance of endothelial function. The development of PAT and interest in other aspects of endothelial function such as circulating biomarkers relating to thrombosis and inflammation may prove to be easier methods of assessing endothelial function. If an easier method could be found then (presuming it showed similar prognostic value as FMD in large-scale studies) perhaps this would have more widespread clinical applicability. Indeed, in our unit, FMD is only used in research studies and is not used at all clinically. The standardization of the method is of key importance with regards to whether FMD can truly penetrate the clinical arena. Secondly, should endothelial dysfunction be used as an end-point to guide therapy or should it be simply thought of as another risk factor? And if so, are there any other potential therapies which might independently modulate endothelial function? Finally, does improving endothelial function lead to improved clinical outcomes in both primary and secondary prevention?

In summary, and in answer to the question posed by the title of this review, there is evidence to suggest that reversal of endothelial dysfunction might still be a target which might improve cardiovascular outcomes in the modern era, however, we do not yet have convincing evidence that it does as yet. We know that reversal is possible, but whether it is beneficial in identifying a higher risk group in primary prevention (in addition to traditional risk factors) or as a target in secondary prevention remains a question with an as yet elusive answer. It may be that FMD (and other measures of endothelial dysfunction) is more of a marker of overall cardiovascular health (predicting adverse outcome similarly to biomarkers such as B-type natriuretic peptide and troponin), rather than a therapeutic target itself. Nevertheless, there is ample evidence that therapies that improve cardiovascular outcome (by various pathways), also seem to improve endothelial function. Given the prognostic value of FMD, it would seem logical that at least some of these beneficial effects may be mediated by an improvement in endothelial function. However, as long the most validated measurement of endothelial function (FMD) cannot reach widespread use clinically, it will remain difficult to promote the idea that reversal of endothelial dysfunction should be a primary target of treatment in its own right. Indeed, to answer the question posed in the title of this review, we believe that while reversal of endothelial dysfunction is an attractive target in modern cardiology, we still require further studies to ascertain whether directly targeting reversal of endothelial dysfunction is a worthwhile target in modern cardiology.

**REFERENCES**

1 **Furchgott RF**, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980; **288**: 373-376 [PMID: 6253831]

2 **Murad F**. The nitric oxide-cyclic GMP signal transduction system for intracellular and intercellular communication. *Recent Prog Horm Res* 1994; **49**: 239-248 [PMID: 7511827]

3 **Kielstein JT**, Bode-Böger SM, Frölich JC, Ritz E, Haller H, Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. *Circulation* 2003; **107**: 1891-1895 [PMID: 12681993 DOI: 10.1161/01.CIR.0000060496.23144.A7]

4 **Rubanyi GM**, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. *Am J Physiol* 1986; **250**: H822-H827 [PMID: 3010744]

5 **Lüscher TF**, Boulanger CM, Dohi Y, Yang ZH. Endothelium-derived contracting factors. *Hypertension* 1992; **19**: 117-130 [PMID: 1737645]

6 **Brunner H**, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Lüscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DJ. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 2005; **23**: 233-246 [PMID: 15662207]

7 **Cox DA**, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. *Circulation* 1989; **80**: 458-465 [PMID: 2527643]

8 **Ludmer PL**, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med* 1986; **315**: 1046-1051 [PMID: 3093861 DOI: 10.1056/NEJM198610233151702]

9 **Okumura K**, Yasue H, Matsuyama K, Ogawa H, Morikami Y, Obata K, Sakaino N. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. *J Am Coll Cardiol* 1992; **19**: 752-758 [PMID: 1545069]

10 **Wilkinson IB**, Webb DJ. Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. *Br J Clin Pharmacol* 2001; **52**: 631-646 [PMID: 11736874]

11 **Silva BM**, Neves FJ, Rocha NG, Cagy M, de Souza MN, da Nóbrega AC. Intra- and inter-tester reproducibility of venous occlusion plethysmography: comparison between a manual and a semi-automatic method of blood flow analysis. *Physiol Meas* 2009; **30**: 1267-1279 [PMID: 19822924 DOI: 10.1088/0967-3334/30/11/010]

12 **Sidhu JS**, Newey VR, Nassiri DK, Kaski JC. A rapid and reproducible on line automated technique to determine endothelial function. *Heart* 2002; **88**: 289-292 [PMID: 12181226]

13 **Anderson TJ**, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC. Close relation of endothelial function in the human coronary and peripheral circulations. *J Am Coll Cardiol* 1995; **26**: 1235-1241 [PMID: 7594037]

14 **Hamburg NM**, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. *Circulation* 2008; **117**: 2467-2474 [PMID: 18458169 DOI: 10.1161/CIRCULATIONAHA.107.748574]

15 **Bonetti PO**, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. *J Am Coll Cardiol* 2004; **44**: 2137-2141 [PMID: 15582310 DOI: 10.1016/j.jacc.2004.08.062]

16 **Schnabel RB**, Schulz A, Wild PS, Sinning CR, Wilde S, Eleftheriadis M, Herkenhoff S, Zeller T, Lubos E, Lackner KJ, Warnholtz A, Gori T, Blankenberg S, Münzel T. Noninvasive vascular function measurement in the community: cross-sectional relations and comparison of methods. *Circ Cardiovasc Imaging* 2011; **4**: 371-380 [PMID: 21551420 DOI: 10.1161/CIRCIMAGING.110.961557]

17 **Reddy KG**, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. *J Am Coll Cardiol* 1994; **23**: 833-843 [PMID: 8106687]

18 **Celermajer DS**, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. *J Am Coll Cardiol* 1994; **24**: 1468-1474 [PMID: 7930277]

19 **Celermajer DS**, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. *J Am Coll Cardiol* 1994; **24**: 471-476 [PMID: 8034885]

20 **Nitenberg A**, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. *Diabetes* 1993; **42**: 1017-1025 [PMID: 8513969]

21 **McVeigh GE**, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 1992; **35**: 771-776 [PMID: 1511805]

22 **Nathan DM**, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. *N Engl J Med* 2003; **348**: 2294-2303 [PMID: 12788993 DOI: 10.1056/NEJMoa022314]

23 **Zeiher AM**, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. *Circulation* 1995; **92**: 1094-1100 [PMID: 7648652]

24 **Celermajer DS**, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation* 1993; **88**: 2149-2155 [PMID: 8222109]

25 **Celermajer DS**, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. *N Engl J Med* 1996; **334**: 150-154 [PMID: 8531969 DOI: 10.1056/NEJM199601183340303]

26 **Panza JA**, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N Engl J Med* 1990; **323**: 22-27 [PMID: 2355955 DOI: 10.1056/NEJM199007053230105]

27 **Quyyumi AA**, Mulcahy D, Andrews NP, Husain S, Panza JA, Cannon RO. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. *Circulation* 1997; **95**: 104-110 [PMID: 8994424]

28 **Casino PR**, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. The role of nitric oxide in endothelium-dependent vasodilation of hypercholesterolemic patients. *Circulation* 1993; **88**: 2541-2547 [PMID: 8252665]

29 **Heitzer T**, Ylä-Herttuala S, Luoma J, Kurz S, Münzel T, Just H, Olschewski M, Drexler H. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. *Circulation* 1996; **93**: 1346-1353 [PMID: 8641023]

30 **Lerman A**, Zeiher AM. Endothelial function: cardiac events. *Circulation* 2005; **111**: 363-368 [PMID: 15668353 DOI: 10.1161/01.CIR.0000153339.27064.14]

31 **Yeboah J**, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. *Circulation* 2007; **115**: 2390-2397 [PMID: 17452608 DOI: 10.1161/CIRCULATIONAHA.106.678276]

32 **Hassan A**, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. *Brain* 2003; **126**: 424-432 [PMID: 12538408]

33 **Ochodnicky P**, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, de Zeeuw D. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. *J Nephrol* ; **19**: 246-258 [PMID: 16874683]

34 **Salles GF**, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. *Hypertension* 2007; **50**: 723-728 [PMID: 17635853 DOI: 10.1161/HYPERTENSIONAHA.107.093120]

35 **Vita JA**, Keaney JF. Endothelial function: a barometer for cardiovascular risk? *Circulation* 2002; **106**: 640-642 [PMID: 12163419]

36 **Donald AE**, Halcox JP, Charakida M, Storry C, Wallace SM, Cole TJ, Friberg P, Deanfield JE. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. *J Am Coll Cardiol* 2008; **51**: 1959-1964 [PMID: 18482664 DOI: 10.1016/j.jacc.2008.02.044]

37 **Charakida M**, de Groot E, Loukogeorgakis SP, Khan T, Lüscher T, Kastelein JJ, Gasser T, Deanfield JE. Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. *Eur Heart J* 2013; **34**: 3501-3507 [PMID: 23821401 DOI: 10.1093/eurheartj/eht223]

38 **Harris RA**, Padilla J, Rink LD, Wallace JP. Variability of flow-mediated dilation measurements with repetitive reactive hyperemia. *Vasc Med* 2006; **11**: 1-6 [PMID: 16669406]

39 **Ghiadoni L**, Faita F, Salvetti M, Cordiano C, Biggi A, Puato M, Di Monaco A, De Siati L, Volpe M, Ambrosio G, Gemignani V, Muiesan ML, Taddei S, Lanza GA, Cosentino F. Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. *J Hypertens* 2012; **30**: 1399-1405 [PMID: 22525207 DOI: 10.1097/HJH.0b013e328353f222]

40 **Charakida M**, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. *Eur Heart J* 2010; **31**: 2854-2861 [PMID: 20864485 DOI: 10.1093/eurheartj/ehq340]

41 **Anderson TJ**. Prognostic significance of brachial flow-mediated vasodilation. *Circulation* 2007; **115**: 2373-2375 [PMID: 17485590 DOI: 10.1161/CIRCULATIONAHA.107.697045]

42 **Anderson KM**, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. *Am Heart J* 1991; **121**: 293-298 [PMID: 1985385]

43 **Suzuki T**, Hirata K, Elkind MS, Jin Z, Rundek T, Miyake Y, Boden-Albala B, Di Tullio MR, Sacco R, Homma S. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). *Am Heart J* 2008; **156**: 405-410 [PMID: 18657678 DOI: 10.1016/j.ahj.2008.02.022]

44 **Yeboah J**, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. *Circulation* 2009; **120**: 502-509 [PMID: 19635967 DOI: 10.1161/CIRCULATIONAHA.109.864801]

45 **Rossi R**, Nuzzo A, Origliani G, Modena MG. Prognostic role of flow-mediated dilation and cardiac risk factors in post-menopausal women. *J Am Coll Cardiol* 2008; **51**: 997-1002 [PMID: 18325438 DOI: 10.1016/j.jacc.2007.11.044]

46 **Shechter M**, Shechter A, Koren-Morag N, Feinberg MS, Hiersch L. Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. *Am J Cardiol* 2014; **113**: 162-167 [PMID: 24169007 DOI: 10.1016/j.amjcard.2013.08.051]

47 **Shimbo D**, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco R, Homma S. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. *Atherosclerosis* 2007; **192**: 197-203 [PMID: 16762358 DOI: 10.1016/j.atherosclerosis.2006.05.005]

48 **Lind L**, Berglund L, Larsson A, Sundström J. Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. *Circulation* 2011; **123**: 1545-1551 [PMID: 21444885 DOI: 10.1161/CIRCULATIONAHA.110.984047]

49 **Anderson TJ**, Charbonneau F, Title LM, Buithieu J, Rose MS, Conradson H, Hildebrand K, Fung M, Verma S, Lonn EM. Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. *Circulation* 2011; **123**: 163-169 [PMID: 21200002 DOI: 10.1161/CIRCULATIONAHA.110.953653]

50 **Suwaidi JA**, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation* 2000; **101**: 948-954 [PMID: 10704159]

51 **Halcox JP**, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. *Circulation* 2002; **106**: 653-658 [PMID: 12163423]

52 **Heitzer T**, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 2001; **104**: 2673-2678 [PMID: 11723017]

53 **Chan SY**, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. *J Am Coll Cardiol* 2003; **42**: 1037-1043 [PMID: 13678927]

54 **Lavi S**, Bae JH, Rihal CS, Prasad A, Barsness GW, Lennon RJ, Holmes DR, Lerman A. Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques. *Heart* 2009; **95**: 1525-1530 [PMID: 19497916 DOI: 10.1136/hrt.2009.166017]

55 **Choi BJ**, Prasad A, Gulati R, Best PJ, Lennon RJ, Barsness GW, Lerman LO, Lerman A. Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. *Eur Heart J* 2013; **34**: 2047-2054 [PMID: 23569198 DOI: 10.1093/eurheartj/eht132]

56 **Patti G**, Pasceri V, Melfi R, Goffredo C, Chello M, D'Ambrosio A, Montesanti R, Di Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. *Circulation* 2005; **111**: 70-75 [PMID: 15630038 DOI: 10.1161/01.CIR.0000151308.06673.D2]

57 **Muiesan ML**, Salvetti M, Paini A, Monteduro C, Galbassini G, Poisa P, Porteri E, Agabiti-Rosei C, Paderno V, Belotti E, Rizzoni D, Castellano M, Agabiti-Rosei E. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. *J Hypertens* 2008; **26**: 1612-1618 [PMID: 18622240 DOI: 10.1097/HJH.0b013e328304b083]

58 **Brevetti G**, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. *Circulation* 2003; **108**: 2093-2098 [PMID: 14530195 DOI: 10.1161/01.CIR.0000095273.92468.D9]

59 **Gokce N**, Keaney JF, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. *Circulation* 2002; **105**: 1567-1572 [PMID: 11927524]

60 **Naghavi M**, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. *Circulation* 2003; **108**: 1772-1778 [PMID: 14557340 DOI: 10.1161/01.CIR.0000087481.55887.C9]

61 **Naghavi M**, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. *Circulation* 2003; **108**: 1664-1672 [PMID: 14530185 DOI: 10.1161/01.CIR.0000087480.94275.97]

62 **Koenig W**, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. *Arterioscler Thromb Vasc Biol* 2007; **27**: 15-26 [PMID: 17082488 DOI: 10.1161/01.ATV.0000251503.35795.4f]

63 **Zeiher AM**, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. *Circulation* 1995; **91**: 941-947 [PMID: 7850978]

64 **Bogaty P**, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. *Circulation* 1994; **90**: 5-11 [PMID: 8026037]

65 **Tousoulis D**, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. *Heart* 2006; **92**: 441-444 [PMID: 16159981 DOI: 10.1136/hrt.2005.066936]

66 **Fichtlscherer S**, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient. *Circulation* 2004; **110**: 1926-1932 [PMID: 15451794 DOI: 10.1161/01.CIR.0000143378.58099.8C]

67 **Careri G**, Nerla R, Di Monaco A, Russo G, Stazi A, Villano A, Sestito A, Lanza GA, Crea F. Clinical correlates and prognostic value of flow mediated dilation in patients with non-ST segment elevation acute coronary syndromes. *Am J Cardiol* 2013; **111**: 51-57 [PMID: 23062313 DOI: 10.1016/j.amjcard.2012.08.049]

68 **Bissinger A**, Grycewicz T, Grabowicz W, Lubiński A. Endothelial function and left ventricular remodeling in diabetic and non-diabetic patients after acute coronary syndrome. *Med Sci Monit* 2011; **17**: CR73-CR77 [PMID: 21278691]

69 **Marti CN**, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. *J Am Coll Cardiol* 2012; **60**: 1455-1469 [PMID: 22999723 DOI: 10.1016/j.jacc.2011.11.082]

70 **Michel T**. NO way to relax: the complexities of coupling nitric oxide synthase pathways in the heart. *Circulation* 2010; **121**: 484-486 [PMID: 20083685 DOI: 10.1161/CIR.0b013e3181d1e24e]

71 **Ma LN**, Zhao SP, Gao M, Zhou QC, Fan P. Endothelial dysfunction associated with left ventricular diastolic dysfunction in patients with coronary heart disease. *Int J Cardiol* 2000; **72**: 275-279 [PMID: 10716138]

72 **Ramsey MW**, Goodfellow J, Jones CJ, Luddington LA, Lewis MJ, Henderson AH. Endothelial control of arterial distensibility is impaired in chronic heart failure. *Circulation* 1995; **92**: 3212-3219 [PMID: 7586306]

73 **Mitchell GF**, Tardif JC, Arnold JM, Marchiori G, O'Brien TX, Dunlap ME, Pfeffer MA. Pulsatile hemodynamics in congestive heart failure. *Hypertension* 2001; **38**: 1433-1439 [PMID: 11751731]

74 **Damy T**, Ratajczak P, Shah AM, Camors E, Marty I, Hasenfuss G, Marotte F, Samuel JL, Heymes C. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. *Lancet* 2004; **363**: 1365-1367 [PMID: 15110495 DOI: 10.1016/S0140-6736(04)16048-0]

75 **Tarro Genta F**, Eleuteri E, Temporelli PL, Comazzi F, Tidu M, Bouslenko Z, Bertolin F, Vigorito C, Giannuzzi P, Giallauria F. Flow-mediated dilation normalization predicts outcome in chronic heart failure patients. *J Card Fail* 2013; **19**: 260-267 [PMID: 23582092 DOI: 10.1016/j.cardfail.2013.01.014]

76 **Meyer B**, Mörtl D, Strecker K, Hülsmann M, Kulemann V, Neunteufl T, Pacher R, Berger R. Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. *J Am Coll Cardiol* 2005; **46**: 1011-1018 [PMID: 16168284 DOI: 10.1016/j.jacc.2005.04.060]

77 **Katz SD**, Hryniewicz K, Hriljac I, Balidemaj K, Dimayuga C, Hudaihed A, Yasskiy A. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. *Circulation* 2005; **111**: 310-314 [PMID: 15655134 DOI: 10.1161/01.CIR.0000153349.77489.CF]

78 **Takishima I**, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, Saito Y, Watanabe K, Watanabe Y, Mishina H, Obata JE, Kawabata K, Tamaru S, Kugiyama K. Predictive value of serial assessment of endothelial function in chronic heart failure. *Int J Cardiol* 2012; **158**: 417-422 [PMID: 21371765 DOI: 10.1016/j.ijcard.2011.01.059]

79 **Sartori C**, Allemann Y, Scherrer U. Pathogenesis of pulmonary edema: learning from high-altitude pulmonary edema. *Respir Physiol Neurobiol* 2007; **159**: 338-349 [PMID: 17532272 DOI: 10.1016/j.resp.2007.04.006]

80 **Ungvári Z**, Gupte SA, Recchia FA, Bátkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. *Curr Vasc Pharmacol* 2005; **3**: 221-229 [PMID: 16026319]

81 **Hollenberg SM**, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Bromet D, Satran A, Costanzo MR. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. *J Heart Lung Transplant* 2004; **23**: 265-271 [PMID: 15019634 DOI: 10.1016/S1053-2498(03)00150-5]

82 **Hollenberg SM**, Klein LW, Parrillo JE, Scherer M, Burns D, Tamburro P, Oberoi M, Johnson MR, Costanzo MR. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. *Circulation* 2001; **104**: 3091-3096 [PMID: 11748106]

83 **Shechter M**, Matetzky S, Arad M, Feinberg MS, Freimark D. Vascular endothelial function predicts mortality risk in patients with advanced ischaemic chronic heart failure. *Eur J Heart Fail* 2009; **11**: 588-593 [PMID: 19406838 DOI: 10.1093/eurjhf/hfp053]

84 **Fischer D**, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, Drexler H. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. *Eur Heart J* 2005; **26**: 65-69 [PMID: 15615801 DOI: 10.1093/eurheartj/ehi001]

85 **de Berrazueta JR**, Guerra-Ruiz A, García-Unzueta MT, Toca GM, Laso RS, de Adana MS, Martín MA, Cobo M, Llorca J. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. *Eur J Heart Fail* 2010; **12**: 477-483 [PMID: 20354033 DOI: 10.1093/eurjhf/hfq036]

86 **Akar JG**, Al-Chekakie MO, Fugate T, Moran L, Froloshki B, Varma N, Santucci P, Wilber DJ, Matsumura ME. Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy. *Heart Rhythm* 2008; **5**: 1229-1235 [PMID: 18774094 DOI: 10.1016/j.hrthm.2008.05.027]

87 **Böhm M**. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? *Am J Cardiol* 2007; **100**: 38J-44J [PMID: 17666197 DOI: 10.1016/j.amjcard.2007.05.013]

88 **Dzau VJ**. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. *Basic Res Cardiol* 1993; **88 Suppl 1**: 1-14 [PMID: 8395169]

89 **Siragy HM**, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. *Hypertension* 2000; **35**: 1074-1077 [PMID: 10818067]

90 **Erdös EG**. The angiotensin I converting enzyme. *Fed Proc* 1977; **36**: 1760-1765 [PMID: 191298]

91 **Zhang X**, Scicli GA, Xu X, Nasjletti A, Hintze TH. Role of endothelial kinins in control of coronary nitric oxide production. *Hypertension* 1997; **30**: 1105-1111 [PMID: 9369263]

92 **Vanhoutte PM**. [Endothelial dysfunction and coronary heart disease. Interaction of endothelium and thrombocytes]. *Schweiz Rundsch Med Prax* 1993; **82**: 1161-1166 [PMID: 8248687]

93 **Hornig B**, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. *Circulation* 1997; **95**: 1115-1118 [PMID: 9054837]

94 **Mancini GB**, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. *Circulation* 1996; **94**: 258-265 [PMID: 8759064]

95 **Prasad A**, Husain S, Quyyumi AA. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin. *J Am Coll Cardiol* 1999; **33**: 796-804 [PMID: 10080484]

96 **Higashi Y**, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. *J Am Coll Cardiol* 2000; **35**: 284-291 [PMID: 10676671]

97 **Wassmann S**, Hilgers S, Laufs U, Böhm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. *Arterioscler Thromb Vasc Biol* 2002; **22**: 1208-1212 [PMID: 12117739]

98 **Ghiadoni L**, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. *Hypertension* 2003; **41**: 1281-1286 [PMID: 12719441 DOI: 10.1161/01.HYP.0000070956.57418.22]

99 **Tzemos N**, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. *Cardiovasc Ther* 2009; **27**: 151-158 [PMID: 19604249 DOI: 10.1111/j.1755-5922.2009.00085.x]

100 **Takagi H,** Umemoto T. A meta-analysis of randomized controlled trials of telmisartan for flow-mediated dilatation. *Hypertens Res* 2014 [PMID: 24718299 DOI: 10.1038/hr.2014.81]

101 **Farquharson CA**, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. *Circulation* 2000; **101**: 594-597 [PMID: 10673249]

102 **Ullian ME**. The role of corticosteriods in the regulation of vascular tone. *Cardiovasc Res* 1999; **41**: 55-64 [PMID: 10325953]

103 **Macdonald JE**, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. *Heart* 2004; **90**: 765-770 [PMID: 15201246 DOI: 10.1136/hrt.2003.017368]

104 **Abiose AK**, Mansoor GA, Barry M, Soucier R, Nair CK, Hager D. Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. *Am J Cardiol* 2004; **93**: 1564-1566 [PMID: 15194040 DOI: 10.1016/j.amjcard.2004.03.015]

105 **Fujimura N**, Noma K, Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Mikami S, Maruhashi T, Iwamoto Y, Kihara Y, Chayama K, Kato H, Liao JK, Higashi Y. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. *Clin Pharmacol Ther* 2012; **91**: 289-297 [PMID: 22205191 DOI: 10.1038/clpt.2011.227]

106 **Maron BA**, Leopold JA. Mineralocorticoid receptor antagonists and endothelial function. *Curr Opin Investig Drugs* 2008; **9**: 963-969 [PMID: 18729003]

107 **Tzemos N**, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. *Circulation* 2001; **104**: 511-514 [PMID: 11479245]

108 **Pasini AF**, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, Pasini A, Cominacini M, Cominacini L. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. *Am J Hypertens* 2008; **21**: 1251-1257 [PMID: 18772860 DOI: 10.1038/ajh.2008.260]

109 **Matsuda Y**, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. *Am Heart J* 2000; **140**: 753-759 [PMID: 11054621 DOI: 10.1067/mhj.2000.110093]

110 **Frielingsdorf J**, Seiler C, Kaufmann P, Vassalli G, Suter T, Hess OM. Normalization of abnormal coronary vasomotion by calcium antagonists in patients with hypertension. *Circulation* 1996; **93**: 1380-1387 [PMID: 8641027]

111 **Rubanyi GM**, Vanhoutte PM. Calcium and activation of the release of endothelium-derived relaxing factor. *Ann N Y Acad Sci* 1988; **522**: 226-233 [PMID: 3288050]

112 **Haynes WG**, Clarke JG, Cockcroft JR, Webb DJ. Pharmacology of endothelin-1 in vivo in humans. *J Cardiovasc Pharmacol* 1991; **17 Suppl 7**: S284-S286 [PMID: 1725356]

113 **Cardillo C**, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. *Circulation* 2002; **105**: 452-456 [PMID: 11815427]

114 **Tiryaki O**, Usalan C, Buyukhatipoglu H, Sayiner ZA, Kilisli H. Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients. *Clin Exp Hypertens* 2012; **34**: 145-152 [PMID: 21967026 DOI: 10.3109/10641963.2011.577491]

115 **Beckman JA**, Liao JK, Hurley S, Garrett LA, Chui D, Mitra D, Creager MA. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. *Circ Res* 2004; **95**: 217-223 [PMID: 15178637 DOI: 10.1161/01.RES.0000134628.96682.9b]

116 **Agewall S**, Hernberg A. Atorvastatin normalizes endothelial function in healthy smokers. *Clin Sci (Lond)* 2006; **111**: 87-91 [PMID: 16608440 DOI: 10.1042/CS20060033]

117 **Ostad MA**, Eggeling S, Tschentscher P, Schwedhelm E, Böger R, Wenzel P, Meinertz T, Munzel T, Warnholtz A. Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. *Atherosclerosis* 2009; **205**: 227-232 [PMID: 19150064 DOI: 10.1016/j.atherosclerosis.2008.11.032]

118 **Gounari P**, Tousoulis D, Antoniades C, Kampoli AM, Stougiannos P, Papageorgiou N, Roulia G, Stefanadi E, Siasos G, Tsioufis C, Stefanadis C. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. *Int J Cardiol* 2010; **142**: 87-91 [PMID: 19200613 DOI: 10.1016/j.ijcard.2008.12.067]

119 **Laufs U**, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. *Circulation* 1998; **97**: 1129-1135 [PMID: 9537338]

120 **Verma S**, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. *Circulation* 2002; **106**: 913-919 [PMID: 12186793]

121 **Pitocco D**, Zaccardi F, Tarzia P, Milo M, Scavone G, Rizzo P, Pagliaccia F, Nerla R, Di Franco A, Manto A, Rocca B, Lanza GA, Crea F, Ghirlanda G. Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. *Diabetes Obes Metab* 2013; **15**: 427-431 [PMID: 23167274 DOI: 10.1111/dom.12041]

122 **Lamendola P**, Nerla R, Pitocco D, Villano A, Scavone G, Stazi A, Russo G, Di Franco A, Sestito A, Ghirlanda G, Lanza GA, Crea F. Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus. *Atherosclerosis* 2013; **226**: 157-160 [PMID: 23146293 DOI: 10.1016/j.atherosclerosis.2012.10.051]

123 **Kao MP**, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. *J Am Soc Nephrol* 2011; **22**: 1382-1389 [PMID: 21719783 DOI: 10.1681/ASN.2010111185]

124 **Modena MG**, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. *J Am Coll Cardiol* 2002; **40**: 505-510 [PMID: 12142118]

**P-Reviewers:** Sandow SL, Sicari R **S-Editor:** Song XX **L-Editor:** **E-Editor:**

**Table 1 Large studies evaluating the prognostic value of flow-mediated dilation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Number of patients | Cohort | Asymptomatic Patients? | Length of follow-up (mo) | Outcome | Result | Independent value of FMD? |
| Rossi *et al*[[45](#_ENREF_45)] | 2264 | Post-menopausal women | ✓ | 45 ± 13 | CV death, MI, revascularisation, TIA, stroke | FMD was a predictor of MACE independently of traditional cardiac risk factors. | ✓ |
| Patti *et al*[[56](#_ENREF_56)] | 136 | Patients with single-vessel coronary artery disease undergoing PCI | ✗ | 6 | In-stent restenosis | Patients with impaired FMD were more likely to suffer in-stent restenosis. | ✓ |
| Gokce *et al*[[59](#_ENREF_59)] | 187 | Patients undergoing vascular surgery | ✗ | 1 | CV death, MI, unstable angina, ventricular fibrillation, stroke, raised troponin | FMD was an independent predictor of MACE in the immediate post-operative period. | ✓ |
| Brevetti *et al*[[58](#_ENREF_58)] | 139 | Patients with peripheral arterial disease | ✗ | 23 ± 10 | CV death, MI, revascularisation, TIA, critical limb ischaemia | FMD was an independent predictor of events over the follow-up period. | ✓ |
| Chan *et al*[[53](#_ENREF_53)] | 152 | Patients with coronary artery disease | ✗ | 34 ± 10 | CV death, MI, revascularisation, claudication | FMD was a strong independent predictor of risk even accounting for carotid plaque burden. | ✓ |
| Shimbo *et al*[[47](#_ENREF_47)] | 842 | Asymptomatic multi-ethnic cohort | ✓ | 36 | Vascular death, MI, stroke | FMD was able to predict adverse events but not independently. | ✗ |
| Suzuki *et al*[[43](#_ENREF_43)] | 819 | Asymptomatic multi-ethnic cohort including patients with metabolic syndrome | ✓ | 81 ± 21 | Vascular death, MI, stroke | Patients with the combination of metabolic syndrome and endothelial dysfunction had a significantly worse outcome. | ✗ |
| Yeboah *et al*[[44](#_ENREF_44)] | 2792 | Mixed cohort of patients > 65 yr | ✗ | 60 | CVD death, MI, stroke, congestive heart failure, claudication, revascularisation | FMD was an independent predictor of risk but added little to traditional risk stratification. | ✓ |
| Muiesan *et al*[[57](#_ENREF_57)] | 172 | Hypertensive patients | ✗ | 95 ± 37 | CV death, MI, revascularisation, arrhythmia, TIA, critical limb ischaemia, retinal artery occlusion | FMD below median was independently associated with adverse outcome. | ✓ |
| Shechter *et al*[[46](#_ENREF_46)] | 618 | Healthy subjects (mixed) | ✓ | 55.2 ± 21.6 | CV death, MI, stroke, congestive revascularisation | FMD predicted adverse outcome independently. | ✓ |
| Katz *et al*[[77](#_ENREF_77)] | 259 | Heart failure patients (LVEF < 40% and NYHA class 2-3) | ✗ | 28 | Death or cardiac transplantation | FMD is associated with increased adverse outcome in ischaemic and non-ischaemic heart failure. | ✓ |

PCI: Percutaneous coronary intervention; MACE: Adverse major cardiovascular events; MI: Myocardial infarction; TIA: Transient ischaemic attack; FMD: Flow-mediated dilation.

**Table 2 Selected studies examining pharmacological reversal of endothelial dysfunction**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Ref.** | **Drug** | **Cohort** | **Design** | **Results** |
| Mancini *et al*[[94](#_ENREF_94)] | Quinapril | 105 normotensive patients with coronary artery disease | Randomised double-blind, placebo controlled | Quinapril improved endothelial function compared to placebo as measured by coronary artery diameter response to acetylcholine |
| Higashi *et al*[[96](#_ENREF_96)] | Various ACE inhibitors, beta-blockers, calcium channel blockers and diuretics | 296 hypertensive patients | Multi-centre cohort study | ACE inhibitors significantly improved endothelial dependent vasodilatation compared to other drug classes as measured by forearm blood flow |
| Wassmann *et al*[[97](#_ENREF_97)] | Candesartan, felodipine | 47 patients with high cholesterol | Randomised double-blind, placebo controlled | Candesartan improved forearm blood flow compared to felodipine or placebo |
| Ghiadoni *et al*[[98](#_ENREF_98)] | Nifedipine, amlodipine  Perindopril, telmisartan, atenolol, nebivolol | 168 patients with hypertension | Randomized, single-blind, parallel-group | Only perindopril improved FMD (although perindopril, telmisartan, nifedipine and amlodipine reduced oxidative stress and increased plasma antioxidant capacity) |
| Tzemos *et al*[[99](#_ENREF_99)] | Valsartan, amlodipine | 25 hypertensive patients | Randomised double-blind, crossover | Valsartan improved forearm blood flow |
| Takagi *et al*[[100](#_ENREF_100)] | Telmisartan | Mixed; 398 patients | Meta-analysis of 7 studies | Statistically significant increase in FMD by 48.7% |
| Farquaharson *et al*[[101](#_ENREF_101)] | Spironolactone | 10 patients with NYHA class I-II heart failure | Randomised, double-blind placebo-controlled crossover study | Spironolactone improved forearm blood flow compared to placebo |
| MacDonald *et al*[[103](#_ENREF_103)] | Spironolactone | 43 patients with NYHA class I-II heart failure | Randomised, double-blind crossover study | Spironolactone improved forearm blood flow compared to placebo |
| Abiose *et al*[[104](#_ENREF_104)] | Spironolactone | 20 patients with NYHA class III-IV congestive heart failure | Cohort study | Spironolactone improved FMD at 4 wk with a sustained improvement at 8 wk |
| Tzemos *et al*[[107](#_ENREF_107)] | Nebivolol, atenolol | 12 hypertensive patients | Randomised, double-blind crossover study | Only nebivolol was able to improve endothelial dependent vasodilation |
| Pasini *et al*[[108](#_ENREF_108)] | Nebivolol, atenolol | 40 hypertensive patients with 40 controls | Randomised double-blind parallel group | FMD improved only in the group treated with nebivolol |
| Matsuda *et al*[[109](#_ENREF_109)] | Carvedilol | 29 patients with coronary artery disease | Randomised, placebo controlled | Carvedilol significantly improved FMD after 4 mo treatment |
| Agewall *et al*[[116](#_ENREF_116)] | Atorvastatin | 20 healthy smokers, 20 healthy non-smokers | Open label placebo controlled randomised cross-over | Smokers had a lower baseline FMD. Atorvastatin improved FMD in smokers but had no effect in non-smokers |
| Ostad *et al*[[117](#_ENREF_117)] | Atorvastatin, ezetimibe | 58 patients with coronary artery disease | Double-blind, randomised, parallel group | High-dose atorvastatin improved FMD significantly more than low dose atorvastatin + ezetimibe independently of improvement in LDL cholesterol |
| Gounari *et al*[[118](#_ENREF_118)] | Rosuvastatin, ezetimibe | Patients with heart failure | Double-blind, placebo controlled, cross-over trial | Rosuvastatin caused a significant improvement of FMD compared to ezetimibe and independent of LDL cholesterol and baseline brachial artery diameter |
| Pitocco *et al*[[121](#_ENREF_121)] | Metformin | 42 type 1 diabetics without overt cardiovascular disease | Randomised double-blind, placebo controlled | Significant improvement in FMD by 1.32% compared to placebo |
| Lamendola *et al*[[122](#_ENREF_122)] | Ranolazine | 30 type 2 (non-insulin dependent) diabetics without overt cardiovascular disease | Randomised double-blind, placebo controlled | Significant improvement in FMD compared to placebo after 2 wk of ranolazine therapy |
| Kao *et al*[[123](#_ENREF_123)] | Allopurinol | 67 patients with CKD stage 3 and LV hypertrophy | Randomized, double-blind, parallel-group | Significant improvement in FMD compared to placebo after 9 mo of allopurinol therapy |

FMD: Flow-mediated dilation.